

***pfhrp2* and *pfhrp3* gene deletions that affect malaria rapid diagnostic tests  
for *Plasmodium falciparum*: analysis of archived blood samples from three  
African countries**

**Authors:** Rebecca Thomson<sup>1\*</sup>, Khalid B Beshir<sup>1</sup>, Jane Cunningham<sup>2</sup>, Frank Baiden<sup>1</sup>, Jameel Bharmal<sup>1</sup>,  
Katia J Bruxvoort<sup>1,3</sup>, Catherine Maiteki-Sebuguzi<sup>4</sup>, Seth Owusu-Agyei<sup>1,5</sup>, Sarah G Staedke<sup>1</sup>, Heidi  
Hopkins<sup>1</sup>

**Author affiliations:**

<sup>1</sup> London School of Hygiene & Tropical Medicine, London, United Kingdom

<sup>2</sup> World Health Organization, Geneva, Switzerland

<sup>3</sup> Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, USA

<sup>4</sup> Infectious Disease Research Collaboration, Kampala, Uganda

<sup>5</sup> University of Health and Allied Sciences, Kintampo Health Research Centre, Kintampo, Ghana

\* **Corresponding author:** Rebecca Thomson, [rebecca.thomson@lshtm.ac.uk](mailto:rebecca.thomson@lshtm.ac.uk)

**Summary:**

*pfhrp2* gene deletions render *Plasmodium falciparum* parasites undetectable to malaria rapid diagnostic tests detecting histidine-rich protein 2. *pfhrp2* deletions were detected in archived blood samples from Tanzania and Uganda, while no samples from Ghana were found to be *pfhrp2*-negative.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract:

### Background

Malaria rapid diagnostic tests (mRDT) that target histidine-rich protein 2 (HRP2) are important tools for *Plasmodium falciparum* diagnosis. Parasites with *pfhrp2/3* gene deletions threaten the use of these mRDTs, and have been reported in Africa, Asia, and South America. We studied blood samples from three African countries to determine if these gene deletions were present.

### Methods

We analysed 911 dried blood spots from Ghana (165), Tanzania (176) and Uganda (570). *P. falciparum* infection was confirmed by 18SrDNA polymerase-chain reaction (PCR), and *pfhrp2/3* genes were genotyped. True *pfhrp2/3* gene deletions were confirmed if samples were (1) microscopy positive, (2) 18SrDNA PCR positive, (3) positive for *merozoite surface protein* genes by PCR, or positive by loop-mediated isothermal amplification, and (4) quantitative PCR positive with > 5 parasites/ $\mu$ l.

### Results

No *pfhrp2/3* deletions were detected in samples from Ghana, but deletions were identified in Tanzania (three *pfhrp2*; two *pfhrp3*) and Uganda (seven *pfhrp2*; two *pfhrp3*). Of the 10 samples with *pfhrp2* deletions, nine tested negative by HRP2-based mRDT.

### Discussion

The presence of *pfhrp2/3* deletions in Tanzania and Uganda, along with reports of *pfhrp2/3*-deleted parasites in neighbouring countries, reinforces the need for systematic surveillance to monitor the reliability of mRDTs in malaria-endemic countries.

**Key words:** HRP2, HRP3, *pfhrp2*, *pfhrp3*, histidine, malaria, rapid diagnostic test, diagnosis, deletion, mutation, false-negative, Ghana, Tanzania, Uganda

## Background

Prompt and accurate diagnosis of malaria is crucial for malaria case-management and control and elimination programmes. While malaria diagnosis was historically based on symptoms alone, since 2010 WHO guidelines state that parasite-based diagnosis of malaria should be confirmed before treatment is given [1]. While quality-assured microscopy remains the gold standard for diagnosis of symptomatic malaria, malaria rapid diagnostic tests (mRDTs), detecting malaria antigen(s), require less training, no specialised equipment and play an important role in malaria case-management. The use of mRDTs has grown substantially since they were first developed in the 1990s, and mRDTs are currently used in the public health care sector in all 91 countries with malaria transmission [2].

The majority of mRDTs currently on the market detect histidine-rich protein 2 (HRP2), a parasite antigen produced throughout the life cycle of *Plasmodium falciparum*, in a blood sample [3]. In general, HRP2-based mRDTs are more sensitive and stable than mRDTs based on other *Plasmodium* antigens, and so are the mRDT of choice in most endemic countries where *P. falciparum* malaria predominates [4].

The accuracy of HRP2-based mRDTs can be affected by factors including low parasite density (which can cause false-negative results), and antigen persisting in the bloodstream after successful treatment of a prior clinical episode (which can cause clinically false-positive results). While false-negative mRDT results have been attributed primarily to the tests' limit of detection, recent reports have confirmed that genetic variation of *P. falciparum* can also affect mRDT performance [5, 6].

Over the past decade *P. falciparum* strains that do not express HRP2 have been documented. The first confirmed parasites that lacked the *pfhrp2* gene were identified in the Amazon Basin in Peru in 2010, with 40% of *P. falciparum* samples testing negative for the gene [7]. Since then, similar parasites have been reported from other areas in South America [8, 9], Central America [10], India and South-East Asia [11, 12], West Africa [13-15], and East and Central Africa [5, 16-19]. In Africa, the highest reported prevalence of *pfhrp2* deletions was in Eritrea, where 62% of samples that tested positive by microscopy were found to lack the *pfhrp2* gene [5]. While fewer studies have confirmed *pfhrp2* deletions among West African countries, a 2015 study in Ghana showed that 29% of samples lacked the *pfhrp2* gene [15]. To date, there are no published reports of *pfhrp2* deletions in Tanzania; however *pfhrp2* deletions were reported in 6.4% of samples from children in Democratic Republic of Congo (DRC) [16], and 1% of microscopy-positive samples from a study in Rwanda [18]. An unpublished study from Uganda reported 1.7% *pfhrp2* deletions among 1,493 microscopy-positive *P. falciparum* samples [20]. Marked heterogeneity in the prevalence of *pfhrp2* deletions within and

between countries has also been described; the prevalence of *pfhrp2* deletions was reported to range from 0% to 25% between eight states in India [11], and from 0% to 22% in different regions of the DRC [16].

Parasites that do not express the HRP2 protein can cause false-negative results by HRP2-based mRDTs[6]. The HRP2 protein has an epitope which shows cross-reactivity with HRP3, also expressed by *P. falciparum*. Therefore, HRP2-based mRDTs sometimes detect infections in *pfhrp2*-deleted parasites due to the presence of HRP3, especially at higher parasite densities [21]. However, the absence of both HRP2 and HRP3 renders the parasites undetectable by HRP2-based mRDTs.

As the epidemiology of *pfhrp2* and *pfhrp3* deletions is still largely unknown, sampling strategies and molecular assessment are needed to determine the extent of these deletions in endemic areas, and to assess their effect, if any, on routine clinical care of malaria patients. While awaiting the implementation of prospective surveillance, this paper reports on stored *P. falciparum* samples from three countries, Ghana, Tanzania, and Uganda.

Accepted Manuscript

## Methods

This study analysed *P. falciparum* parasites identified in human blood samples from three malaria studies in Ghana, Tanzania and Uganda. For each source study, this analysis included all available samples recorded as negative by HRP2-based mRDT and positive by microscopy; plus a random selection of available samples recorded as positive by both mRDT and microscopy, of those negative by both microscopy and mRDT, and of those positive by mRDT and negative by microscopy. In total 911 samples were analysed.

### Sample collection

Samples in Ghana were collected as part of an mRDT clinical evaluation in 2009 and 2010 [22]. Information about the survey is shown in Table 1. Three hundred and ninety-seven samples were collected (Table 2), of which 165 were selected for this study (Figure 1).

Samples in Tanzania were collected during surveys in 2010 as part of an evaluation of mRDT implementation in public health facilities (IMPACT2). Samples were selected from a household survey [23] and a health facility survey [24]. In total, 10,535 samples had mRDT and microscopy results as well as DBS (Table 2): 8,812 from the household survey and 1,723 from the health facility survey. A total of 176 samples were selected for analysis (Figure 1).

Samples from Uganda were collected as part of the School-Based Treatment with ACT to Reduce Transmission (START-IPT) study from 2014 to 2015, a cluster-randomised trial to measure the effects of intermittent preventive treatment for malaria [25]. A total of 8,922 microscopy and DBS samples were collected from cross-sectional surveys of community residents in control and intervention groups (Table 1). mRDTs were performed on participants who were febrile or had history of fever in the previous 48 hours. Unique to the Uganda study, loop-mediated isothermal amplification (LAMP) for *P. falciparum* was performed on specified proportions of samples, after DNA extraction from DBS by standard methods with Chelex 100 Resin (Bio-Rad, Hercules, CA, USA), resulting in 5,258 samples with LAMP results. Of the samples with microscopy, LAMP and mRDT results, 570 were selected for this study (Figure 1).

Written informed consent was obtained from all participants or participants' caregivers. The study in Ghana was approved by the Institutional Ethics Committee of the Kintampo Health Research Centre and the ethics review committees of the Ghana Health Service. The IMPACT2 study in Tanzania was approved by the Institutional Review Board of Ifakara Health Institute. Ethical approval in Uganda was obtained from the Uganda National Council for Science and Technology;

Makerere University School of Medicine Research and Ethics Committee; the School of Biological and Biomedical Sciences Ethics Committee, Durham University (UK); and the University of California, San Francisco Committee on Human Research. All three studies obtained ethics approval from the London School of Hygiene and Tropical Medicine (LSHTM).

### **Microscopy**

Thick blood smears were stained with 2% or 10% Giemsa and read in duplicate by two microscopists who were blinded to the initial reading and to the mRDT results. Discrepant results were resolved by a third microscopist. Parasites were counted against 200 white blood cells and were considered negative if no asexual parasites or gametocytes were found after examining 100 fields. Microscopy was performed at Kintampo Health Research Centre clinical laboratory in Ghana, Ifakara Health Institute, Bagamoyo, in Tanzania, and Makerere University Molecular Research Laboratory, Mulago Hospital, Kampala in Uganda.

### **Sample storage**

Samples in all three countries were stored in sealed plastic bags with desiccant at ambient temperature. Samples were selected in the countries of origin, and DBS from all countries were couriered to LSHTM in 2016. Molecular analysis was conducted at LSHTM between October 2016 and November 2017.

### **Molecular analysis**

#### *DNA extraction*

DNA was extracted from all DBS using QIAasympy according to the manufacturer's protocol (QIAGEN, Germany), using a previously published protocol [21]. A 3mm diameter punch was taken from each DBS and placed in a deep well plate. Buffer ATL (180ul) and proteinase (20ul) were added to each well and mixed at 900 rpm at 56°C for 15 minutes in a thermomixer. The plates were then placed into the QIAasympy compartments for DNA extraction and the eluted DNA was stored at -20°C.

#### *Amplification of *pfhrp2* and *pfhrp3**

Parasite presence was confirmed using standard PCR targeting the 18S ribosomal RNA gene of *P. falciparum* (18SrDNA) as previously published [26]. The limit of detection was 0.1 parasites/μl. For samples found positive, genotyping of *pfhrp2* and *prhrp3* (Genbank accession numbers PF3D7\_0831800 and PF3D7-1372200 respectively) was then conducted using amended PCR

conditions and primers published by Baker, *et al.* [27]. Briefly, a semi-nested amplification was performed using the following conditions: 94°C for 10 minutes, then 94°C for 50 seconds, 50°C for 50 seconds, and 60°C for 1 minute. The reaction mixture contained 5 µl of extracted genomic DNA, 200 nM of each primer, 2 mM of MgCl<sub>2</sub>, 200 nM of each dNTP, 1X NH<sub>4</sub> reaction buffer (Bioline, UK) and 1.25U of AmpliTaq Gold (ThermoFisher Scientific, UK).

#### *Confirmation of pfhrp2 and pfhrp3 deletion*

To confirm the deletion of *pfhrp2* and *pfhrp3* genes, PCR of two other single copy genes was performed. For samples from Ghana and Tanzania, PCR of *merozoite surface protein 1 (msp1)* and *msp2* genes was conducted on samples which were *pfhrp2*-negative using previously-published methods [28, 29]. Samples from Uganda had been tested by LAMP [25] and therefore *msp* confirmation was not performed.

#### *Quantification of parasitemia by qPCR*

The parasitemia of *pfhrp2*-negative samples was quantified by *PgMET* qPCR as described in Beshir *et al.*, 2010 [30]. The limit of detection for *pfhrp2* by this method is 5 parasites/µl [17].

#### *Classification of pfhrp2/pfhrp3 genes*

Samples were considered to be truly negative for *pfhrp2* or *pfhrp3* if deletions were identified as above and: i) they were positive by microscopy, and ii) they tested positive by 18SrDNA PCR, and iii) *msp* genes were detected by PCR (Ghana, Tanzania) or the sample was positive by LAMP (Uganda). Furthermore, only samples above the limit of detection of 5 parasites/µl by qPCR were considered true *pfhrp2/3*-negatives, since samples below this parasite density may have given false-negative results by *pfhrp2/3* PCR.

## **Results**

#### *Percentage of samples testing positive for P. falciparum in study samples, by detection method*

Among the samples from Ghana, 107/165 (64.9%) were recorded as positive by mRDT and 82/165 (49.7%) by microscopy (Figure 2). In Tanzania, 72/171 (53.8%) samples were recorded as positive by mRDT, while 140/176 (79.6%) were positive by microscopy (five samples did not have mRDT results).

Of the 570 Uganda samples, 258/570 (45.3%) were recorded as positive by mRDT, and 203 (35.6%) were positive by microscopy.

Microscopy and mRDT results for the samples included in this analysis are presented in Figure 1. Among the samples available from Ghana, none were recorded as positive by microscopy and negative by mRDT. In Tanzania, about one third of the samples selected for analysis were positive by microscopy and negative by mRDT (60/171, 35.1%), while in Uganda 125/570 (21.9%) samples were recorded as positive by microscopy and negative by RDT.

Microscopy-determined parasite density in Ghana ranged from 371 to 1,500,000 parasites/ $\mu$ L (mean 128,505; median 37,960.5). In Tanzania the range was 2 to 9,249 parasites/ $\mu$ L (mean 1,079; median 60.5). Microscopy-determined parasite densities were not recorded for Uganda samples.

#### *Presence of pfhrp2/pfhrp3 gene deletions*

Of the 165 samples from Ghana, 154 (93.3%) tested positive by 18SrDNA and 80 (48.5%) tested positive by both 18SrDNA and microscopy (Figure 3). All 80 samples tested positive for *pfhrp2*, and only one sample tested negative for *pfhrp3*. No Ghanaian sample was both positive by microscopy and negative by mRDT (Table 3).

Of the 176 samples from Tanzania, 148 (85.1%) were positive by 18SrDNA PCR, of which 137 were positive by microscopy. After applying the confirmation criteria for *pfhrp2/3* deletions, three samples were found to have *pfhrp2* deletions. Two samples had *pfhrp3* deletions; both of these also had *pfhrp2* deletions (Table 3).

Of the 570 samples from Uganda, 416 (73.0%) were positive by PCR, of which 194 were microscopy-positive. After applying the confirmation criteria seven samples were found to have *pfhrp2* deletions. Two samples had *pfhrp3* deletions; both of these were also negative for *pfhrp2*.

Overall, nine of the ten *pfhrp2*-negative samples tested positive by microscopy and negative by mRDT (Table 3). Six of these samples had an intact *pfhrp3* gene while four did not. One sample from Tanzania was positive by both the ICT Diagnostics mRDT and microscopy, and was negative for *pfhrp3*. The parasite concentration of these ten samples ranged from 7.3 to 3,800 parasites/ $\mu$ L by qPCR. No sample was negative for *pfhrp3* and positive for *pfhrp2*.

## Discussion

*P. falciparum* parasites lacking the genes coding for histidine-rich proteins, which are detected by commonly used mRDTs, pose a threat to malaria control and elimination programmes. This report presents an analysis of *pfhrp2/3* in archived human blood samples from three African countries, alongside microscopy and mRDT results obtained in the primary studies from which the samples were drawn. Molecular analysis identified low levels of *pfhrp2* and *pfhrp3* gene deletions in samples from Tanzania (collected in 2010) and Uganda (2014-15), while no evidence of deletions was found in samples from Ghana (2009-10).

Of the ten *pfhrp2*-negative samples identified in this study, nine were recorded as negative by HRP2-based mRDT, seven by the mRDT used in Uganda and two by the mRDT in Tanzania. The exception was one sample from Tanzania, which was negative for both *pfhrp2* and *pfhrp3*, but positive by HRP2-based mRDT; possible explanations for this could be a data recording error, or a false-positive mRDT due to cross reactions with human anti-mouse antibodies or rheumatoid factor [31]. All mRDTs used in the original studies performed well in the WHO product testing rounds of the corresponding study years; however, the panel detection score of the mRDTs used in Uganda and Ghana was higher than that of the mRDT used in Tanzania [4, 32], which might explain, at least partly, why parasite prevalence by mRDT was lower than by microscopy in Tanzania. Also, most samples from Tanzania were from asymptomatic people, while samples from the other two countries were from symptomatic patients, resulting in lower parasite density among Tanzanian *P. falciparum*-positive samples.

Of the nine *pfhrp2*-negative samples that tested negative by mRDT, six had intact *pfhrp3*. While it is well-documented that HRP2-based mRDTs may give false-negative results in the absence of *pfhrp2* [5, 11, 13], it has also been found that cross reaction with epitopes on HRP3 can produce positive mRDT results [7, 15, 27], especially at concentrations above 1,000 parasites/ $\mu$ l [17]. Cross-reactivity of HRP3 on HRP2-based RDTs has also been shown to vary between mRDT brands [33]. In this study, the parasite densities in the six *pfhrp2*-negative/ *pfhrp3*-positive samples ranged from 7.3 to 69.3 parasites/ $\mu$ l, likely too low to be detected by mRDTs even if HRP3 was present. Parasites with deletions in both *pfhrp2* and *pfhrp3* genes are undetectable by HRP2-based RDTs [34], and therefore the presence of *pfhrp3* deletions in these populations is significant.

In this study a true *pfhrp2* negative sample was defined as the absence of *pfhrp2* in a sample that tested positive for malaria by microscopy and positive for *P. falciparum* either by LAMP or two other single copy genes. This produces a conservative estimate of *pfhrp2* deletion; some other studies

have reported *pfhrp2* deletions based only on failure to amplify the *pfhrp2* gene by PCR, without also confirming parasite presence with two other single copy genes by PCR, which may produce more alarming results [8, 9, 35]. We also chose a qPCR cut-off of five parasites/ $\mu$ L, the limit of detection for *pfhrp2* PCR, to determine true *pfhrp2* negative samples [17]. Any samples with a parasite density below this threshold may have produced false-negatives for *pfhrp2* PCR and could not be confirmed as true *pfhrp2* negatives. While the majority of published studies have not applied this criterion in their identification of *pfhrp2* deletions, doing so produces a conservative and more confident definition of *pfhrp2* deletion [34]. Indeed the number of samples found to be *pfhrp2*-negative would have been higher without this cut-off (Fig 3).

While this is the first report of *pfhrp2* gene deletions in Tanzania, findings from neighbouring Rwanda [36], Kenya [21], DRC [16], and nearby Eritrea [5, 19] indicate that the phenomenon is present in the region. There are a few reports of *pfhrp2* gene deletions in other countries in West Africa, including a study using archived samples from Mali [13] and one in Senegal [14]. While our study did not show any deletions in Ghana, two other studies in Ghana have reported alarming results of 29% [15] and 75% [37] although the latter was among a small sample of only eight children. Samples from the former study were collected in 2015, from Gold Coast and Accra, both in the south of the country, while samples from the latter study were collected in Accra, also in 2015. Samples in our study were collected in 2010 in Kintampo, in the middle of Ghana, so the differing areas and times of sample collection could explain the different findings.

Of note, the majority of these studies were not designed specifically to investigate the epidemiology of *pfhrp2/3* deletions; deletion analysis was conducted on samples that had been collected to address other primary objectives, which is also the case for the study reported here. While reports of *pfhrp2/3* deletions in neighbouring or nearby countries are suggestive, prevalence within a geographic area can be highly heterogeneous [11, 16], and the design of surveillance efforts should take this into account.

The *pfhrp2* gene amino acid sequence and repeats have been shown to vary substantially across different geographic regions [38]. This study looked only at presence versus absence of *pfhrp2/3* genes. Genomic sequencing of exons and flanking regions would provide more information on sequence diversity among these samples. Even *pfhrp2*-positive samples may harbour genetic diversity with implications for mRDT detection. While diversity in the *pfhrp2* gene has not been found to affect mRDT affinity in samples with parasite densities of clinical significance [11, 39], it has been shown to affect mRDT results at densities below 200 parasites per  $\mu$ L [27].

The phenomenon of *pfhrp2/3* gene deletions poses a substantial threat to malaria control and could reverse the gains made through the rapid expansion of mRDT uptake over the past decade [40]. Prescriber adherence to test results, especially negative test results, has been a key focus of mRDT implementation efforts to date [41, 42]. False-negative mRDT results lead to under-diagnosis of malaria, and if patients who are infected but test negative do not receive antimalarial treatment, severe disease and even death may result; and the *pfhrp2*-deleted parasites in their bloodstream may then be taken up by female *Anopheles* mosquitoes and transmitted to others [6]. Models have demonstrated that newly introduced *pfhrp2*-negative parasites can spread rapidly through a community if HRP2-based mRDTs are the only diagnostic tool used to guide treatment practices [40]. Using publicly available genomic data generated from genetic crosses, the absence of fitness cost for *hrp2*-negative parasites has recently been reported [43].

In malaria-endemic countries, assessment and surveillance of *pfhrp2/3* deletions and their impact must be undertaken effectively and efficiently, alongside multiple other public health and malaria control priorities. To this end, WHO has published a protocol for implementing surveys designed to measure *pfhrp2*-deleted parasites among malaria suspects [44]. WHO guidelines state that if the prevalence of *pfhrp2* gene deletions that cause false-negative HRP2-based RDT results in a representative sample is higher than 5%, HRP2-based mRDTs should be replaced with a new diagnostic tool [44]. In such cases mRDTs that target other antigens, such as those detecting pan-LDH or Pf-pLDH, may be considered. However, pLDH-based mRDTs are generally less sensitive and heat stable than HRP2-based RDTs and this trade-off must be weighed in considering a switch. The 5% threshold in the WHO guidance is estimated to be the prevalence at which the benefits of non-HRP2-based diagnostics for detecting *pfhrp2*-deleted parasites outweighs the reduced sensitivity of these tools to detect wild-type parasites.

This study has several limitations. The blood samples analysed were collected as part of other malaria studies which were not designed to study *pfhrp2/3* deletions nor to measure prevalence of these mutations. DBS samples were purposively selected from the available samples and were not representative of the total original study populations. Furthermore the samples were taken from different human populations, including a household survey of asymptomatic individuals and exit interviews of febrile patients who sought care at health facilities; in Ghana these surveys targeted children while in Tanzania and Uganda they targeted individuals of all ages. Samples were collected at different time points, from 2010 in Ghana to 2015 in Uganda, which may affect the findings if the epidemiology of gene deletions has changed over time. This makes it impossible to directly compare results across the three countries. Samples had been stored for several years before molecular

analysis in non-refrigerated conditions, however, a set of criteria were followed to determine *pfhrp2/3* deletions to compensate for this. This molecular analysis focussed on exon 2, as this is the main part of the gene that affects RDT performance. However also targeting the region across exon 1 and flanking genes would provide greater confirmatory evidence of gene deletions and enable detection of partial gene deletions on chromosome breaking points. Rather than measuring prevalence of gene deletions, this study serves as one indicator, using rigorous laboratory methods to determine whether any mutated parasites are present in available samples from the study areas.

This report documents the presence of *pfhrp2/3* gene deletions in *P. falciparum* in archived blood samples from two East African countries, Tanzania and Uganda. Further studies and surveillance will be essential to better understand the epidemiology of these parasites, as well as to guide future decisions about diagnostic tools and strategies. Although no conclusions about the prevalence of *pfhrp2/3* deletions can be drawn from this study, the fact that only a few deleted parasites were identified suggests that HRP2-based mRDTs are still a valid diagnostic tool in these countries. However, together with other reports documenting the presence and potential spread of such parasites in nearby areas, this study reinforces the WHO call for systematic surveillance to monitor the reliability of mRDTs [44].

**Acknowledgments:** We gratefully acknowledge the assistance of the clinical staff and patients in all of the studies contributing data for this analysis. We thank Daniel Chandramohan, Catherine Goodman, Patrick Kachur, David Schellenberg, and Jayne Webster for leading the primary studies from which the samples analysed in this report were taken; Levi Mugenyi, Sam Nsohya, Emmanuel Ruhanya, Andrea Rehman, Matilda Tivura, David Dosoo, for assistance in selecting and shipping the samples; and Paul Snell and Sham Lal for development and management of the central data repository; and Colin Sutherland for advice and comments on the submitted manuscript.

**Funding statement and statement of the independence of researchers from funders:** The Ghana and Tanzania primary studies and this analysis were supported by the ACT Consortium, which was funded through a grant from the Bill and Melinda Gates Foundation to the London School of Hygiene & Tropical Medicine. The START-IPT was funded by the Medical Research Council, Department for International Development and the Wellcome Trust under the Joint Global Health Trials scheme (MR/K00736X/1). This award is part of the EDCTP2 programme supported by the European Union. Part of the laboratory work was supported by Rosemary Weir prize awarded to KBB by Department

of Infection and Biology. The study funders had no role in the study design, implementation, analysis, manuscript preparation, or decision to submit this article for publication.

**Competing interests:** All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the submitted work other than the Bill & Melinda Gates Foundation; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

## References

1. World Health Organization. Guidelines for the treatment of malaria. 2nd edition. Geneva: 2010.
2. World Health Organization. Good practices for selecting and procuring rapid diagnostic tests for malaria. Geneva: 2011.
3. Desakorn V, Dondorp AM, Silamut K, Pongtavornpinyo W, Sahassananda D, Chotivanich K, et al. Stage-dependent production and release of histidine-rich protein 2 by *Plasmodium falciparum*. *Trans R Soc Trop Med Hyg.* 2005;99(7):517-24. Epub 2005/05/07. doi: 10.1016/j.trstmh.2004.11.014. PubMed PMID: 15876442.
4. World Health Organization. Malaria rapid diagnostic test performance: results for WHO product testing of malaria RDTs: round 6 (2014-15). 2015.
5. Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major Threat to Malaria Control Programs by *Plasmodium falciparum* Lacking Histidine-Rich Protein 2, Eritrea. *Emerging infectious diseases.* 2018;24(3):462-70. Epub 2018/02/21. doi: 10.3201/eid2403.171723. PubMed PMID: 29460730; PubMed Central PMCID: PMC5823352.
6. World Health Organization. False-negative RDT results and implications of new reports of *P.falciparum* histidine-rich protein 2/3 gene deletions. Geneva: 2017.
7. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large proportion of *P. falciparum* isolates in the Amazon region of Peru lack *pfhrp2* and *pfhrp3*: implications for malaria rapid diagnostic tests. *PloS one.* 2010;5(1):e8091. doi: 10.1371/journal.pone.0008091. PubMed PMID: 20111602; PubMed Central PMCID: PMC2810332.
8. Akinyi Okoth S, Abdallah JF, Ceron N, Adhin MR, Chandrabose J, Krishnalall K, et al. Variation in *Plasmodium falciparum* Histidine-Rich Protein 2 (*Pfhrp2*) and *Plasmodium falciparum* Histidine-Rich Protein 3 (*Pfhrp3*) Gene Deletions in Guyana and Suriname. *PloS one.* 2015;10(5):e0126805. Epub 2015/05/16. doi: 10.1371/journal.pone.0126805. PubMed PMID: 25978499; PubMed Central PMCID: PMC4433255.
9. Maltha J, Gamboa D, Bendezu J, Sanchez L, Cnops L, Gillet P, et al. Rapid diagnostic tests for malaria diagnosis in the Peruvian Amazon: impact of *pfhrp2* gene deletions and cross-reactions. *PloS one.* 2012;7(8):e43094. Epub 2012/09/07. doi: 10.1371/journal.pone.0043094. PubMed PMID: 22952633; PubMed Central PMCID: PMC3429466.
10. Fontecha G, Mejia RE, Banegas E, Ade MP, Mendoza L, Ortiz B, et al. Deletions of *pfhrp2* and *pfhrp3* genes of *Plasmodium falciparum* from Honduras, Guatemala and Nicaragua. *Malaria journal.* 2018;17. doi: 10.1186/s12936-018-2470-7. PubMed PMID: WOS:000443331300003.
11. Bharti PK, Chandel HS, Ahmad A, Krishna S, Udhayakumar V, Singh N. Prevalence of *pfhrp2* and/or *pfhrp3* Gene Deletion in *Plasmodium falciparum* Population in Eight Highly Endemic States in India. *PloS one.* 2016;11(8):e0157949. doi: 10.1371/journal.pone.0157949. PubMed PMID: 27518538; PubMed Central PMCID: PMC4982695.

12. Li P, Xing H, Zhao Z, Yang Z, Cao Y, Li W, et al. Genetic diversity of *Plasmodium falciparum* histidine-rich protein 2 in the China-Myanmar border area. *Acta tropica*. 2015;152:26-31. Epub 2015/08/25. doi: 10.1016/j.actatropica.2015.08.003. PubMed PMID: 26297799; PubMed Central PMCID: PMC4918506.
13. Koita OA, Doumbo OK, Ouattara A, Tall LK, Konare A, Diakite M, et al. False-negative rapid diagnostic tests for malaria and deletion of the histidine-rich repeat region of the *hrp2* gene. *The American journal of tropical medicine and hygiene*. 2012;86(2):194-8. doi: 10.4269/ajtmh.2012.10-0665. PubMed PMID: 22302847; PubMed Central PMCID: PMC3269266.
14. Wurtz N, Fall B, Bui K, Pascual A, Fall M, Camara C, et al. *Pfhrp2* and *pfhrp3* polymorphisms in *Plasmodium falciparum* isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests. *Malaria journal*. 2013;12:34. Epub 2013/01/26. doi: 10.1186/1475-2875-12-34. PubMed PMID: 23347727; PubMed Central PMCID: PMC3571878.
15. Amoah LE, Abankwa J, Oppong A. *Plasmodium falciparum* histidine rich protein-2 diversity and the implications for PfHRP 2: based malaria rapid diagnostic tests in Ghana. *Malaria journal*. 2016;15:101. Epub 2016/02/20. doi: 10.1186/s12936-016-1159-z. PubMed PMID: 26891848; PubMed Central PMCID: PMC4759916.
16. Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, et al. *Pfhrp2*-Deleted *Plasmodium falciparum* Parasites in the Democratic Republic of the Congo: A National Cross-sectional Survey. *The Journal of infectious diseases*. 2017;216(1):36-44. doi: 10.1093/infdis/jiw538. PubMed PMID: 28177502.
17. Beshir KB, Sepulveda N, Bharmal J, Robinson A, Mwanguzi J, Busula AO, et al. *Plasmodium falciparum* parasites with histidine-rich protein 2 (*pfhrp2*) and *pfhrp3* gene deletions in two endemic regions of Kenya. *Scientific Reports*. 2017;7. doi: 10.1038/s41598-017-15031-2. PubMed PMID: WOS:000414569100008.
18. Kozycki CT, Umulisa N, Rulisa S, Mwikarago EI, Musabyimana JP, Habimana JP, et al. False-negative malaria rapid diagnostic tests in Rwanda: impact of *Plasmodium falciparum* isolates lacking *hrp2* and declining malaria transmission. *Malaria journal*. 2017;16. doi: 10.1186/s12936-017-1768-1. PubMed PMID: WOS:000397733300003.
19. Menegon M, L'Episcopia M, Nurahmed AM, Talha AA, Nour BYM, Severini C. Identification of *Plasmodium falciparum* isolates lacking histidine-rich protein 2 and 3 in Eritrea. *Infect Genet Evol*. 2017;55:131-4. Epub 2017/09/12. doi: 10.1016/j.meegid.2017.09.004. PubMed PMID: 28889944.
20. Nsobya S NE, Walakira A, Kiggundu M, Ruhamyankaka E, Arinaitwe E, Kamya M, Grant D and Rosenthal P. Deletions of *pfhrp2* and *pfhrp3* in rdt-negative *plasmodium falciparum* isolates from Uganda American Society of Tropical Medicine and Hygiene 65th Annual Conference, 20162016. Available from: <http://www.astmh.org/ASTMH/media/Documents/Abstracts-1001-1500-ASTMH-2016-Annual-Meeting-Abstract-Book.pdf>.
21. Beshir KB, Sepulveda N, Bharmal J, Robinson A, Mwanguzi J, Busula AO, et al. *Plasmodium falciparum* parasites with histidine-rich protein 2 (*pfhrp2*) and *pfhrp3* gene deletions in two endemic regions of Kenya. *Sci Rep*. 2017;7(1):14718. Epub 2017/11/09. doi: 10.1038/s41598-017-15031-2. PubMed PMID: 29116127; PubMed Central PMCID: PMC45677122.
22. Baiden F, Webster J, Tivura M, Delimini R, Berko Y, Amenga-Etego S, et al. Accuracy of rapid tests for malaria and treatment outcomes for malaria and non-malaria cases among under-five children in rural Ghana. *PloS one*. 2012;7(4):e34073. Epub 2012/04/20. doi: 10.1371/journal.pone.0034073. PubMed PMID: 22514617; PubMed Central PMCID: PMC3325982.
23. Thomson R, Festo C, Johanes B, Kalolella A, Bruxvoort K, Nchimbi H, et al. Has Tanzania Embraced the Green Leaf? Results from Outlet and Household Surveys before and after Implementation of the Affordable Medicines Facility -Malaria. *PloS one*. 2014;9(5):e95607. doi: 10.1371/journal.pone.0095607. PubMed PMID: 24816649.
24. Bruxvoort K, Kalolella A, Nchimbi H, Festo C, Taylor M, Thomson R, et al. Getting antimalarials on target: impact of national roll-out of malaria rapid diagnostic tests on health facility

- treatment in three regions of Tanzania. *Tropical medicine & international health : TM & IH*. 2013;18(10):1269-82. Epub 2013/08/14. doi: 10.1111/tmi.12168. PubMed PMID: 23937722; PubMed Central PMCID: PMC4282336.
25. Staedke SG, Maiteki-Sebuguzi C, Rehman AM, Kigozi SP, Gonahasa S, Okiring J, et al. Assessment of community-level effects of intermittent preventive treatment for malaria in schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial. *Lancet Glob Health*. 2018. Epub 2018/04/18. doi: 10.1016/S2214-109X(18)30126-8. PubMed PMID: 29661635.
26. Snounou G, Singh B. Nested PCR analysis of Plasmodium parasites. *Methods in molecular medicine*. 2002;72:189-203. doi: 10.1385/1-59259-271-6:189. PubMed PMID: 12125116.
27. Baker J, McCarthy J, Gatton M, Kyle DE, Belizario V, Luchavez J, et al. Genetic diversity of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and its effect on the performance of PfHRP2-based rapid diagnostic tests. *The Journal of infectious diseases*. 2005;192(5):870-7. doi: 10.1086/432010. PubMed PMID: 16088837.
28. Snounou GaB, H.P. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. *Parasitology Today*. 1998;14:462-7.
29. Beshir KB, Diallo N, Sutherland CJ. Identifying Recrudescence Plasmodium falciparum in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity. *Sci Rep*. 2018;8(1):10097. Epub 2018/07/06. doi: 10.1038/s41598-018-28179-2. PubMed PMID: 29973679; PubMed Central PMCID: PMC6031682.
30. Beshir KB, Hallett RL, Eziefula AC, Bailey R, Watson J, Wright SG, et al. Measuring the efficacy of anti-malarial drugs in vivo: quantitative PCR measurement of parasite clearance. *Malaria journal*. 2010;9:312. Epub 2010/11/09. doi: 10.1186/1475-2875-9-312. PubMed PMID: 21054863; PubMed Central PMCID: PMC2992070.
31. Gatton ML, Ciketic S, Barnwell JW, Cheng Q, Chiodini PL, Incardona S, et al. An assessment of false positive rates for malaria rapid diagnostic tests caused by non-Plasmodium infectious agents and immunological factors. *PloS one*. 2018;13(5):e0197395. Epub 2018/05/15. doi: 10.1371/journal.pone.0197395. PubMed PMID: 29758050; PubMed Central PMCID: PMC5951549.
32. World Health Organization. Malaria Rapid Diagnostic Test Performance. Summary results of WHO Malaria RDT Product Testing: Rounds 2-3 (2008-2011). Geneva: 2011.
33. World Health Organization. Malaria rapid diagnostic test performance: Results of WHO product testing of malaria RDTs: round 8 (2016-2018). Geneva: 2018.
34. Cheng Q, Gatton ML, Barnwell J, Chiodini P, McCarthy J, Bell D, et al. Plasmodium falciparum parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting. *Malaria journal*. 2014;13:283. Epub 2014/07/24. doi: 10.1186/1475-2875-13-283. PubMed PMID: 25052298; PubMed Central PMCID: PMC4115471.
35. Baldeviano GC, Okoth SA, Arrospide N, Gonzalez RV, Sanchez JF, Macedo S, et al. Molecular Epidemiology of Plasmodium falciparum Malaria Outbreak, Tumbes, Peru, 2010-2012. *Emerging infectious diseases*. 2015;21(5):797-803. Epub 2015/04/22. doi: 10.3201/eid2105.141427. PubMed PMID: 25897626; PubMed Central PMCID: PMC4412223.
36. Kozycki CT, Umulisa N, Rulisa S, Mwikarago EI, Musabyimana JP, Habimana JP, et al. False-negative malaria rapid diagnostic tests in Rwanda: impact of Plasmodium falciparum isolates lacking hrp2 and declining malaria transmission. *Malaria journal*. 2017;16(1):123. doi: 10.1186/s12936-017-1768-1. PubMed PMID: 28320390; PubMed Central PMCID: PMC5359811.
37. Owusu EDA, Djonor SK, Brown CA, Grobusch MP, Mens PF. Plasmodium falciparum diagnostic tools in HIV-positive under-5-year-olds in two ART clinics in Ghana: are there missed infections? *Malaria journal*. 2018;17. doi: 10.1186/s12936-018-2231-7. PubMed PMID: WOS:000426509200002.
38. Ramutton T, Hendriksen IC, Mwanga-Amumpaire J, Mtove G, Olaosebikan R, Tshetu AK, et al. Sequence variation does not confound the measurement of plasma PfHRP2 concentration in African children presenting with severe malaria. *Malaria journal*. 2012;11:276. Epub 2012/08/18.

doi: 10.1186/1475-2875-11-276. PubMed PMID: 22898068; PubMed Central PMCID: PMC3480887.

39. Baker J, Ho MF, Pelecanos A, Gattton M, Chen N, Abdullah S, et al. Global sequence variation in the histidine-rich proteins 2 and 3 of *Plasmodium falciparum*: implications for the performance of malaria rapid diagnostic tests. *Malaria journal*. 2010;9:129. Epub 2010/05/18. doi: 10.1186/1475-2875-9-129. PubMed PMID: 20470441; PubMed Central PMCID: PMC2893195.

40. Gattton M DJ, Chaudhry A, Ciketic S, Cunningham J and Cheng Q. Implications of Parasites Lacking *Plasmodium falciparum* Histidine-Rich Protein 2 on Malaria Morbidity and Control When Rapid Diagnostic Tests are Used for Diagnosis. *Journal of Infectious Diseases*. 2017;215(7):1156-66.

41. Bruxvoort KJ, Leurent B, Chandler CIR, Ansah EK, Baiden F, Bjorkman A, et al. The Impact of Introducing Malaria Rapid Diagnostic Tests on Fever Case Management: A Synthesis of Ten Studies from the ACT Consortium. *The American journal of tropical medicine and hygiene*. 2017;97(4):1170-9. Epub 2017/08/19. doi: 10.4269/ajtmh.16-0955. PubMed PMID: 28820705; PubMed Central PMCID: PMC5637593.

42. Burchett HE, Leurent B, Baiden F, Baltzell K, Bjorkman A, Bruxvoort K, et al. Improving prescribing practices with rapid diagnostic tests (RDTs): synthesis of 10 studies to explore reasons for variation in malaria RDT uptake and adherence. *BMJ Open*. 2017;7(3):e012973. Epub 2017/03/10. doi: 10.1136/bmjopen-2016-012973. PubMed PMID: 28274962; PubMed Central PMCID: PMC5353269.

43. Sepulveda N, Phelan J, Diez-Benavente E, Campino S, Clark TG, Hopkins H, et al. Global analysis of *Plasmodium falciparum* histidine-rich protein-2 (pfrhp2) and pfrhp3 gene deletions using whole-genome sequencing data and meta-analysis. *Infect Genet Evol*. 2018;62:211-9. Epub 2018/05/08. doi: 10.1016/j.meegid.2018.04.039. PubMed PMID: 29729386.

44. World Health Organization. Protocol for estimating the prevalence of pfrhp2/pfrhp3 gene deletions among symptomatic *falciparum* patients with false-negative RDT results Geneva2018. Available from: <http://www.who.int/malaria/publications/atoz/hrp2-deletion-protocol/en/>.

Accepted Article

**Table 1. Characteristics of primary studies from which dried blood spot samples were selected for analysis of *pfhrp2* and *pfhrp3***

Country	Type of survey	Date of sample collection	Study sites	Clinical status of participants	Age range of participants	mRDT manufacturer	Estimated entomological inoculation rate	Reference of study from which samples were collected
Ghana	Health facility	2009 - 2010	Kintampo	Symptomatic	Children aged 6 – 30 months	CareStart (Access Bio)	269 <sup>a</sup>	Baiden et al [22]
Tanzania	Household, health facility	2010	Mbeya, Mtwara and Mwanza regions	Asymptomatic and symptomatic	All ages from six months and above	ICT Diagnostics	10.4-148.6 <sup>b</sup>	Thomson et al [23], Bruxvoort et al, [24]
Uganda	Cross-sectional	2014 - 2015	Jinja district	Symptomatic <sup>c</sup>	All ages	CareStart (Access Bio) (Somerset, NJ)	56.3-61.5	Staedke et al [25]

mRDT = malaria rapid diagnostic test.

<sup>a</sup>The entomological inoculation rate was not assessed in the Ghana study. Data are from Owusu-Agyei S, Asante KP, Adjuik M, Adjei G, Awini E, Adams M, et al.

Epidemiology of malaria in the forest-savanna transitional zone of Ghana. *Malaria journal*. 2009;8:220. Epub 2009/09/30. doi: 10.1186/1475-2875-8-220. PubMed PMID: 19785766; PubMed Central PMCID: PMCPMC2765449.

<sup>b</sup>The entomological inoculation rate was not assessed in the Tanzania study. A range of values are presented as the study in Tanzania was conducted in three different regions with varying malaria transmission. Data are from Maxwell CA, Chambo W, Mwaimu M, Magogo F, Carneiro IA, Curtis CF. Variation of malaria transmission and morbidity with altitude in Tanzania and with introduction of alphacypermethrin treated nets. *Malaria journal*. 2003;2:28. Epub 2003/10/31. doi: 10.1186/1475-2875-2-28. PubMed PMID: 14585106; PubMed Central PMCID: PMCPMC239954.

<sup>c</sup>The survey in Uganda was conducted on symptomatic and asymptomatic people, but malaria rapid diagnostic tests were performed only on symptomatic participants and therefore samples for this study were from symptomatic people.

**Table 2. Study populations from which dried blood spot samples were selected for analysis of *pfhrp2* and *pfhrp3***

<b>Study site</b>	<b>mRDT negative, microscopy negative</b>	<b>mRDT negative, microscopy positive</b>	<b>mRDT positive, microscopy negative</b>	<b>mRDT positive, microscopy positive</b>
Ghana	148	0	58	191
Tanzania	8,319	102	1,663	451
Uganda	2,508	122	1,395	1,235

mRDT = malaria rapid diagnostic test.

**Table 3. Samples with *pfhrp2* and *pfhrp3* deletions among PCR-positive *P. falciparum* samples, by country of origin and results of microscopy and HRP2-based malaria rapid diagnostic test**

	mRDT negative, microscopy negative	mRDT negative, microscopy positive	mRDT positive, microscopy negative	mRDT positive, microscopy positive
<b>Number of PCR positive samples among all samples analysed</b>				
Ghana	50	0	24	80
Tanzania	7	57	4	75
Uganda	176	116	46	78
<b><i>pfhrp</i> gene deletion status among PCR positive samples</b>				
<b>Ghana</b>				
No deletion	50	0	24	80
<i>pfhrp2</i> -/ <i>pfhrp3</i> +	0	0	0	0
<i>pfhrp2</i> +/ <i>pfhrp3</i> -	0	0	0	0
<i>pfhrp2</i> -/ <i>pfhrp3</i> -	0	0	0	0
<b>Tanzania</b>				
No deletion	7	55	4	74
<i>pfhrp2</i> -/ <i>pfhrp3</i> +	0	1	0	0
<i>pfhrp2</i> +/ <i>pfhrp3</i> -	0	0	0	0
<i>pfhrp2</i> -/ <i>pfhrp3</i> -	0	1	0	1
<b>Uganda</b>				
No deletion	176	109	46	78
<i>pfhrp2</i> -/ <i>pfhrp3</i> +	0	5	0	0
<i>pfhrp2</i> +/ <i>pfhrp3</i> -	0	0	0	0
<i>pfhrp2</i> -/ <i>pfhrp3</i> -	0	2	0	0

mRDT = malaria rapid diagnostic test.

**Figure 1. Two-by-two tables showing results of malaria rapid diagnostic tests (mRDT) based on detection of histidine-rich protein 2 (HRP2) and expert microscopy for human blood samples analysed for *pfhrp2/3* genes**

	mRDT positive	mRDT negative
microscopy positive	82	0
microscopy negative	25	58

**Ghana**

	mRDT positive	mRDT negative
microscopy positive	75	60
microscopy negative	17	19

**Tanzania<sup>a</sup>**


	mRDT positive	mRDT negative
microscopy positive	78	125
microscopy negative	180	187

**Uganda**

<sup>a</sup> Five samples from Tanzania had no corresponding mRDT result.

Accepted Manuscript

Figure 2. Percentage of samples positive for *P. falciparum* in study samples, by detection method




mRDT = malaria rapid diagnostic test.

PCR = polymerase chain reaction.

\*denotes kappa value of 0.6 or higher, indicating good agreement between diagnostic methods.

Accepted Manuscript

**Figure 3. Flow diagram showing process of determining *pfhrp2* and *pfhrp3* gene deletion in blood samples from studies in three African countries**



PCR = polymerase chain reaction

*msp* = merozoite surface protein

LAMP = loop mediated isothermal amplification

qPCR = quantitative polymerase chain reaction

\*The first number in each row denotes the number of samples among *pfhrp2*-negative samples; the second denotes the number among *pfhrp3*-negative samples.